As Donald Trump’s threats to impose tariffs on imported pharmaceuticals increase in intensity, the US president will be pleased to hear that Novartis is expanding its manufacturing and R&D footprint in the country with a total investment of $23bn over the next five years.
Key Takeaways
- Novartis says the huge investment means it will produce “100% of its key medicines end-to-end in the US, a significant increase from current levels”
The Switzerland-headquartered giant said that the investment included a newly planned $1.1bn R&D hub in San Diego, CA, which is expected to open between 2028 and 2029
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?